durvalumab,medi1191
astrazeneca
['durva', 'opal']
in phase i fih trial in heavily pretreated patients intralesional medi 1191 combined with durvalumab produced changes in components of immune response and obtained abscopal effect #aacr23 
Born in Majorca. Medical oncologist. Clinical researcher. Focused in lung cancer. World citizen. Major concerns: human inequality and blue planet environment